Biomolecules & Therapeutics
- 제5권1호
- /
- Pages.48-52
- /
- 1997
- /
- 1976-9148(pISSN)
- /
- 2005-4483(eISSN)
Antigenicity Study of CFA-001, cefazolin, a cephalosperin Derivative Produced by an :Enzymatic Semisynthesis
- Park, Jong-Il (Toxicology Research Center, Korea Research Institute of Chemical Technology) ;
- Jeong, Tae-Cheon (Toxicology Research Center, Korea Research Institute of Chemical Technology) ;
- Kim, Hyoung-Chin (Toxicology Research Center, Korea Research Institute of Chemical Technology) ;
-
Han, Sang-Seop
(Toxicology Research Center, Korea Research Institute of Chemical Technology)
;
- Roh, Jung-Koo (Toxicology Research Center, Korea Research Institute of Chemical Technology) ;
- Kim, Jeong-Hwan (R&D Center, Cheil Jedang Inc.) ;
- Jeon, Yeong-Joong (R&D Center, Cheil Jedang Inc.) ;
- Kim, Dal-Hyun (R&D Center, Cheil Jedang Inc.) ;
- Kim, Je-Hak (R&D Center, Cheil Jedang Inc.) ;
-
Park, Kwan-Ha
(Department of Fish Pathology, Ocean Sciences and Technology, Kunsan National University)
- 발행 : 1997.03.01
초록
The antigenic potential of CFA-001, cefazolin, a cephalosporin derivative produced by an enzy-matic semisynthesis, was determined in Hartley guinea pigs. A battery of tests employed consisted of active systemic anaphylaxis (ASA), passive cutaneous anaphylaxis (PCA), and indirect hemagglutination test (IHA). The results were as follows: 1) In ASA, no signs attributable to anaphylaxis was observed in guinea pigs sensitized with CFA-001, whereas OVA-sensitized animals induced severe anaphylactic symptoms; 2) guinea pigs did not produce antibodies against CFA-001 when sensitized with or without Freund's complete adjuvant (FCA) in homologous PCA tests. Meanwhile, antibodies against ovalbumin (OVA) were clearly detected; 3) No CFA-001-specific hemagglutination was observed in the IHA using sera obtained from CFA-001- sensitized guinea pigs. These results suggest that CFA-001 has no antigenicity potential in guinea pigs.